AGN.c has received FDA Orphan Drug Designation for Ifenprodi AGN.c has received FDA Orphan Drug Designation for Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis, while they are also in Phase-1 study of DMT treatment for stroke.
https://twitter.com/StocksNThoughts/status/1603851601416187904
The FDA approval for Ifenprodil comes at the right time, signifiying they are on the right track. Waiting to hear more about the Phase-1 DMT study, which they expect to go smoothly since many safe studies at this level have occured.